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AbstrACt
Objective To investigate the relationship between body 
mass index (BMI) and obesity-related cancers in men and 
women with type 2 diabetes (T2D).
Design Observational cohort study.
setting Primary care.
Participants A total of 52 044 patients with T2D who 
participated in the ZODIAC (Zwolle Outpatient Diabetes 
project Integrating Available Care) study between 1998 
and 2012 was included (49% women). A dataset of 
these patients was linked to available information of the 
Netherlands Cancer Registry to obtain data on cancer 
incidents.
Primary outcome measures Analyses were performed 
for the total group of obesity-related cancers and for 
non-sex-specific and sex-specific obesity-related cancers 
(in men: advanced prostate cancer, in women: ovarian, 
endometrial and postmenopausal breast cancer).
results The median follow-up period in all analyses 
was 3.1 (1.7–5.0) years in men and 3.1 (1.7–5.1) in 
women. During follow-up, 689 men and 914 women were 
diagnosed with an obesity-related cancer. In men, BMI was 
associated with a higher risk of the total group of obesity-
related cancers and non-sex-specific obesity-related 
cancers (HR (per 5 kg/m2 increase) 1.12 (95% CI 1.02 to 
1.23) and HR 1.18 (95% CI 1.06 to 1.31)). No association 
was found with prostate cancer. In women, an association 
between BMI and all obesity-related cancers combined 
and sex-specific obesity-related cancers was present (HR 
1.15 (95% CI 1.08 to 1.22) and HR 1.22 (95% CI 1.14 to 
1.32)). No association with non-sex-specific cancers was 
found in women.
Conclusions BMI is associated with obesity-related 
cancers in men with T2D, except with advanced prostate 
cancer. The results of this study provide reason to 
reconsider the classification of advanced prostate 
cancer as an obesity-related cancer, at least in T2D. 
In women, BMI is associated with the total group of 
obesity-related cancers and with sex-specific obesity-
related cancers.
IntrODuCtIOn 
Type 2 diabetes (T2D) is associated with an 
increased risk for cardiovascular morbidity and 
mortality.1 2 Furthermore, T2D is also related 
to a higher cancer risk.3 4 This increased cancer 
risk appears to be site-specific; a higher risk 
for liver, pancreas, endometrial, colorectal, 
breast and bladder cancer has been reported 
in patients with T2D.3 Whether this increased 
risk is directly related to T2D, caused by longer 
periods of hyperglycaemia and/or elevated 
insulin levels, or indirectly, due to common risk 
factors like obesity, is not clear.3 
According to the World Cancer Research 
Fund, being overweight or obese is related 
to an increased incidence of oesophageal, 
stomach (cardia), colorectal, liver, gall-
bladder, pancreatic and kidney cancer 
in both sexes in the general population. 
Furthermore, being overweight or obese is 
related to an increased incidence of ovarian, 
strengths and limitations of this study
 ► This is the first study investigating sex differences in 
relation between body mass index (BMI) and obesity-
related cancer in a large cohort of patients with type 
2 diabetes (T2D) who are treated in primary care.
 ► A dataset of 71 634 patients with T2D was linked to 
the Netherlands Cancer Registry to obtain data on 
cancer incidents and finally 52  044 patients were 
included in the present study.
 ► Data on BMI were available for 91% of all included 
patients.
 ► The grouping of obesity-related cancers could be 
discussed.
 ► The median follow-up time was relatively short for 
cancer epidemiology.
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endometrial and postmenopausal breast cancer in women 
and to advanced prostate cancer in men.5
Whether there is an association between body mass index 
(BMI) and excess risk of developing obesity-related cancers 
in patients with T2D is unclear. One previous study did 
not find an association between BMI and obesity-related 
cancers in T2D.6 Another study investigated this association 
with colon cancer and found only a significant relationship 
in patients who suffered from obesity for a total duration of 
4 years or more.7
Even more unclear is whether there is a sex differ-
ence in the association between BMI and obesity-related 
cancers in patients with T2D. A large prospective study 
from Sweden reported an association between being 
overweight and obesity with all cancers and gastrointes-
tinal cancers in men. However, in women only an associa-
tion with obesity and both cancer groups was found.8 This 
could indicate that the threshold for BMI to act as a risk 
factor for obesity-related cancer is lower in men compared 
with women with T2D. Therefore, the aim of the present 
study was to investigate the relationship between BMI and 
obesity-related cancers in men and women with T2D and 
specifically non-sex-specific and sex-specific obesity-re-
lated cancers.
MAterIAls AnD MethODs
study group
The study population consisted of patients who were 
included in the Zwolle Outpatient Diabetes project Inte-
grating Available Care (ZODIAC) study. This project 
started in 1998 and was part of a study at that time 
that primarily investigated the effects of shared care in 
patients with T2D treated in primary care in the Zwolle 
region of the Netherlands.9 This shared care initiative 
became the standard care for the Zwolle region in 2002 
and expanded to other regions in the Netherlands in 
the years thereafter. In these regions, general practi-
tioners (GPs) provide data on an annual basis to the 
Diabetes Centre for benchmark and research purposes. 
Patients with only T2D treated in primary care are 
included in the ZODIAC project. The diagnosis of T2D 
was based on the guidelines of the Dutch College of 
General Practitioners (twice a fasting plasma glucose 
level ≥7 mmol/L or once a non-fasting plasma glucose 
level ≥11.1 mmol/L accompanied by symptoms of hyper-
glycaemia). Patients with a very short life expectancy or 
insufficient cognitive capabilities are excluded from 
participation. At the start in 1998, 53 GPs participated 
in this project, and this number increased to more than 
700 GPs in 2012.
For the current study, available information on clin-
ical variables from patients participating for at least 
1 year in the ZODIAC project between 1998 and 2012 
was linked to available information of the Netherlands 
Cancer Registry (NKR) to obtain data on cancer inci-
dents in the years between 1989 and 2012. Information 
from the NKR in the period before 1998 was used to 
exclude patients who were diagnosed with an obesity-re-
lated cancer before entering the ZODIAC study. The 
NKR started in 1989 and records all malignancies based 
on notification by the National Pathology Archive and 
hospital discharge registries in the Netherlands. Basal 
cell carcinoma of the skin, carcinoma in situ of the cervix, 
myelodysplastic syndrome, myeloproliferative disorders 
are not registered in the NCR database. Data on patient 
characteristics, tumour type and grade, and treatment 
Figure 1 Flow chart of inclusion. *For the analyses of the total group of obesity-related cancers, patients diagnosed with a 
non-sex-specific or sex-specific obesity-related cancer before entering the ZODIAC study were excluded. For the non-sex-
specific analysis, only patients with a non-sex-specific cancer before entering the ZODIAC study were excluded. For the sex-
specific cancer analysis, only patients with a sex-specific cancer before entering the ZODIAC study were excluded. BMI, body 
mass index; NKR, the Netherlands Cancer Registry;  ZODIAC, Zwolle Outpatient Diabetes project Integrating Available Care. 
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are collected by specially trained data managers directly 
from the patients’ files in all hospitals in the Nether-
lands. The linking was performed by a trusted third 
party using postal code, full name, date of birth and sex. 
The NKR expects that the number of false-positive and 
the number false-negative for the ZODIAC-NKR linkage 
is both under 1%. The combined ZODIAC-NKR data-
base contains 71 634 patients, of which 10 717 (15%) 
were diagnosed with cancer.
Data collection
For the current study, a database was constructed which 
consisted of both the variables of the ZODIAC project 
and the variables of the NKR. The demographic and 
clinical data which were used in the present study were 
collected as part of ZODIAC project and included: sex, 
age, diabetes duration, HbA1c, serum creatinine, BMI, 
smoking status and the use of metformin, sulfonylurea 
(SU) derivatives and insulin. Information on smoking 
was collected during the check-up of the patient by the 
GP or practice nurse as part of the ZODIAC project 
whereby smoking was documented as yes or no. No data 
concerning previous smoking were available. Baseline was 
defined as the first year that a patient was included in the 
ZODIAC project. Cancer characteristics provided and 
collected by the NKR were cancer origin, incidence date, 
tumour, node, metastases (TNM) stage, morphology and 
type of therapy.
study procedure
The association between BMI and obesity-related cancer 
was investigated for three groups: total group of obesi-
ty-related cancers, non-sex-specific obesity-related cancers 
and sex-specific obesity-related cancers. The non-sex-spe-
cific cancer group consisted of gastric-cardia (Interna-
tional Classification of Diseases (ICD) C16.0), colorectal 
(ICD C18, 19, 20), liver (ICD C22), gall bladder (ICD 
C23), pancreas (ICD C25) and kidney cancer (ICD 
C64) and adenocarcinoma of the oesophagus (ICD 
C15.5+ morphological codes 8140 or 8560). In men, 
the sex-specific cancer group was formed by advanced 
prostate cancers only (ICD C61 +TNM 3 or 4 or Gleason 
score >7) (further referred to as prostate cancer). In 
women, the sex-specific cancer group consisted of ovarian 
Table 1 Baseline characteristics of men and women
Variable Men Women P value*
N 25 811 (49.2) 24 989 (50.8)
Age (years) 64.0 (±11.2) 66.6 (±12.1) <0.001
Diabetes duration 
(years)
2.5 (0.7–5.8) 2.8 (0.8–6.3) <0.001
HbA1c (mmol/mol) 49 (43–55) 49 (43–54) 0.091
Creatinine (µmol/L) 83 (73–95) 68 (59–79) <0.001
Smoking (yes) 8029 (31) 4857 (19) <0.001
BMI (kg/m2) 29.2 (4.6) 30.4 (5.7) <0.001
Use of metformin 
(yes)
14 813 (57) 13 539 (54) <0.001
Use of 
SU derivatives 
(yes)
7977 (31) 7638 (31) 0.408
Use of insulin (yes) 2135 (8) 2512 (10) <0.001
Values are depicted as n (%), mean (±SD) or median 
(IQR). Continuous data were analysed using independent t-tests 
or the Mann-Whitney U test. Categorical variables were analysed 
using χ2 tests.
*P value for the difference between men and women.
BMI, body mass index; SU, sulfonylurea.
Table 2 Regression analyses for all obesity-related cancers in men and women*
Variable
Men Women
Crude
HR (95% CI)
Adjusted
HR (95% CI)
Crude
HR (95% CI)
Adjusted
HR (95% CI)
BMI (per 5 kg/m2) 1.11 (1.01 to 1.22) 1.12 (1.02 to 1.23) 1.14 (1.07 to 1.21) 1.15 (1.08 to 1.22)
Diabetes duration (years) 0.99 (0.97 to 1.01) 0.99 (0.97 to 1.00)
HbA1c (mmol/mol) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.00)
Creatinine (µmol/L) 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.00)
Use of metformin 0.94 (0.80 to 1.10) 0.98 (0.85 to 1.22)
Use of SU derivatives 1.16 (0.98 to 1.37) 1.03 (0.88 to 1.19)
Use of insulin 1.14 (0.84 to 1.54) 1.09 (0.85 to 1.40)
Smoking 1.02 (0.86 to 1.22) 1.11 (0.93 to 1.33)
*Gastric- cardia (ICD C16.0) (events in men: 18, events in women: 3), colorectal (ICD C18, 19, 20) (events in men: 330, events in women: 
247), liver (ICD C22) (events in men: 15, events in women: 8), gall bladder (ICD C23) (events in men: 2, events in women: 7), pancreas (ICD 
C25) (events in men: 59, events in women: 41), kidney cancer (ICD C64) (events in men: 60, events in women: 38) and adenocarcinoma of the 
oesophagus (ICD C15.5+ morphological codes 8140 or 8560) (events in men: 46, events in women: 7). In men supplemented with advanced 
prostate cancers (C61 +TNM 3 or 4 or Gleason score >7) (events in men: 159). In women supplemented with ovarian (ICD C56) (events in 
women: 39), endometrial (ICD C54.1) (events in women: 117) and postmenopausal breast cancer (ICD C50 and age ≥55 years) (events in 
women: 407).
BMI, body mass index; ICD, International Classification of Diseases; SU, sulfonylurea; TNM, tumour, node and metastases. 
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(ICD C56), endometrial (ICD C54.1) and postmeno-
pausal breast cancer (ICD C50) (further referred to as 
ovarian, endometrial and breast cancer). The total group 
of obesity-related cancers consisted of non-sex-specific 
cancers and prostate cancer in men and of non-sex-spe-
cific cancers and ovarian, endometrial and breast cancer 
in women. Postmenopausal breast cancer was in the 
present study defined as breast cancer in women ≥55 
years of age.10 All included cancer cases were histologi-
cally confirmed by a pathologist.
Patients with a BMI <18.5 kg/m2 were excluded in all 
analyses, as undiagnosed cancer may lead to becoming 
underweight (n=130 (0.2%)). Furthermore, patients were 
excluded if they had only baseline data recorded (only one 
check-up by their care provider) (n=18.643 (26.0%)). For 
the analyses of the total group of obesity-related cancers, 
patients diagnosed with a non-sex-specific or sex-specific 
obesity-related cancer before entering the ZODIAC study 
were excluded (n=2061 (2.9%)). For the non-sex-spe-
cific analysis, only patients with a non-sex-specific cancer 
before entering the ZODIAC study were excluded (n=817 
(1.1%)). For the sex-specific cancer analysis, only patients 
with a sex-specific cancer before entering the ZODIAC 
study were excluded (n=1278 (1.8%)) (figure 1).
Clinical endpoint in all analyses was the first obesity-re-
lated cancer after baseline. Patients were not censored 
if they were diagnosed with a non-obesity-related cancer 
during follow-up. The end of follow-up for patients who 
were not diagnosed with cancer was based on the last 
check-up by their GP.
statistical analyses
Statistical analyses were performed using SPSS V.23 for 
Windows (SPSS, Chicago, Illinois, USA) and Stata V.14.0 
for Windows. Multiple imputation analysis was performed 
for missing data on the independent variables, assuming 
that data were missing at random or completely at 
random. All variables of model 2 were included in the 
imputation model and the fully conditional specification 
model in SPSS was used to predict the missing data. Ten 
imputated datasets were created and the pooled results 
are presented. Baseline data are expressed as mean with 
SD or median with IQR for normally distributed and 
non-normally distributed data, respectively. Categorical 
variables are described in numbers and percentages. 
Normal distribution was assessed on the basis of histo-
grams and Q–Q plots. A two-sided P<0.05 was considered 
significant. Cox proportional hazard analyses were used to 
investigate the association between BMI as a continuous 
and categorical variable and obesity-related cancers in 
men and women with T2D, separately. HRs refer to a BMI 
increase of 5kg/m2 in the analyses for BMI as a contin-
uous variable. For the analyses of BMI as a categorical vari-
able, four BMI categories were used (≥18.5–<25.0 kg/m2, 
≥25.0–<30.0 kg/m2, ≥30.0–<35.0 kg/m2, ≥35.0 kg/m2). 
The lowest category was used as reference category. 
Age was used as the time scale in all analyses, because 
the risk of cancer is not proportional with age. Patients T
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entered the analysis at their baseline age and exited at 
their event/censoring age. Two models were used: an 
age-adjusted model (model 1) and a model additionally 
adjusted for diabetes duration, HbA1c, serum creatinine, 
smoking status and the use of metformin, SU derivatives 
and/or insulin (model 2). Furthermore, the analyses for 
model 2 were stratified according to the year of inclusion 
in the ZODIAC cohort. The assumption of proportional 
hazards for baseline predictors was investigated by visual 
inspection of the Schoenfeld residuals.
results
total group of obesity-related cancers
Baseline results for the men and women who are included 
in the analyses for the total group obesity-related cancers 
are described in table 1. In these analyses, 25 811 men 
and 24 989 women were included. Mean age was 64.0 (SD 
11.2) years in men and 66.6 (12.1) years in women. The 
median diabetes duration was higher in women. More 
men than women were current smokers and men had 
a lower BMI than women. A higher percentage of men 
used metformin whereas insulin use was more frequent 
in women. 30.4% of the patients did not use metformin, 
SU derivatives or insulin. These patients were on dietary 
interventions or other diabetes medication. The median 
follow-up period for these patients was 3.1 (1.7–5.0) years 
in men and 3.1 (1.7–5.1) in women. During follow-up, 
689 (2.7%) men and 914 women (3.7%) were diagnosed 
with an obesity-related cancer.
The results of the association between BMI as a contin-
uous variable and the total group of obesity-related 
cancers are described in table 2 for men and women, 
separately. In both men and women, BMI was associ-
ated with a higher risk of obesity-related cancer in the 
Table 4 Regression analyses for non-sex-specific obesity-related cancers in men and women*
Variable
Men Women
Crude
HR (95% CI)
Adjusted
HR (95% CI)
Crude
HR (95% CI)
Adjusted
HR (95% CI)
BMI (per 5 kg/m2) 1.17 (1.05 to 1.30) 1.18 (1.06 to 1.31) 1.01 (0.92 to 1.12) 1.02 (0.92 to 1.13)
Diabetes duration (years) 1.00 (0.97 to 1.02) 0.98 (0.96 to 1.01)
HbA1c (mmol/mol) 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.01)
Creatinine (µmol/L) 1.00 (0.99 to 1.00) 1.00 (0.99 to 1.01)
Use of metformin 0.88 (0.74 to 1.06) 1.16 (0.94 to 1.44)
Use of SU derivatives 1.07 (0.88 to 1.30) 1.15 (0.92 to 1.44)
Use of insulin 1.04 (0.73 to 1.49) 1.19 (0.82 to 1.74)
Smoking 1.09 (0.90 to 1.33) 1.33 (1.01 to 1.76)
*Gastriccardia (ICD C16.0) (events in men: 19, events in women: 3), colorectal (ICD C18, 19, 20) (events in men: 330, events in women: 270), 
liver (ICD C22) (events in men: 15, events in women: 8), gall bladder (ICD C23) (events in men: 2, events in women: 8), pancreas (ICD C25) 
(events in men: 59, events in women: 44), kidney cancer (ICD C64) (events in men: 62, events in women: 45) and adenocarcinoma of the 
oesophagus (ICD C15.5+ morphological codes 8140 or 8560) (events in men: 46, events in women: 7).
BMI, body mass index; ICD, International Classification of Diseases; SU, sulfonylurea.
Table 5 Regression analyses for sex-specific obesity-related cancers in men and women*
Variable
Men Women
Crude
HR (95% CI)
Adjusted
HR (95% CI)
Crude
HR (95% CI)
Adjusted
HR (95% CI)
BMI (per 5 kg/m2) 0.92 (0.74 to 1.15) 0.93 (0.75 to 1.16) 1.22 (1.13 to 1.31) 1.22 (1.14 to 1.32)
Diabetes duration (years) 0.98 (0.95 to 1.02) 0.98 (0.96 to 1.01)
HbA1c (mmol/mol) 0.99 (0.98 to 1.01) 1.00 (0.99 to 1.01)
Creatinine (µmol/L) 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.00)
Use of metformin 1.17 (0.85 to 1.61) 0.86 (0.73 to 1.03)
Use of SU derivatives 1.50 (1.07 to 2.09) 0.93 (0.77 to 1.13)
Use of insulin 1.34 (0.74 to 2.42) 1.05 (0.76 to 1.44)
Smoking 0.81 (0.55 to 1.19) 1.00 (0.79 to 1.27)
*In men supplemented with advanced prostate cancers (C61 +TNM 3 or 4 or Gleason score >7) (events in men: 170). In women supplemented 
with ovarian (ICD C56) (events in women: 39), endometrial (ICD C54.1) (events in women: 119) and postmenopausal breast cancer (ICD C50 
and age ≥55 years) (events in women: 417).
BMI, body mass index; ICD, International Classification of Diseases; SU, sulfonylurea; TNM, tumour, node and metastases.
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age and fully adjusted analyses (in men: HR 1.11 (95% 
CI 1.01 to 1.22) and HR 1.12 (95% CI 1.02 to 1.23), in 
women: HR 1.14 (95% CI 1.07 to 1.21) and HR 1.15 
(95% CI 1.08 to 1.22)). Analysis of BMI as a categorical 
variable showed that in men a BMI of 30.0–35.0 kg/m2 
was associated with a higher risk of obesity-related cancer 
compared with the reference group. In women, a BMI of 
30.0–35.0 kg/m2 and a BMI ≥35.0 kg/m2 were both associ-
ated with a higher risk of obesity-related cancer compared 
with the reference group (table 3).
non-sex-specific obesity-related cancers
In the analyses for non-sex-specific obesity-related cancers, 
25 945 men and 26 099 women were included. Baseline 
results for these patients did not significantly differ from 
the baseline results described in table 1 (data not shown). 
The median follow-up period was 3.1 (1.7–5.0) years in 
men and 3.1 (1.7–5.1) in women. During follow-up, 533 
(2.1%) men and 385 (1.5%) women were diagnosed with 
a non-sex-specific obesity-related cancer.
In men, BMI was associated with a higher risk of 
non-sex-specific obesity-related cancer in the age and 
fully adjusted analyses (HR 1.17 (95% CI 1.05 to 1.30) 
and HR 1.18 (95% CI 1.06 to 1.31)) (table 4). In the 
categorical analyses, a BMI of 30.0–35.0 kg/m2 and a 
BMI ≥35.0 kg/m2 were also associated with a higher risk of 
non-sex-specific obesity-related cancer in men (table 3). 
In women, no significant associations between BMI as a 
continuous or categorical variable and non-sex-specific 
obesity-related cancers were found.
sex-specific obesity-related cancers
In the analyses for sex-specific obesity-related cancers, 
26 226 men and 25 357 women were included. Baseline 
results for these patients did not significantly differ from 
the baseline results described in table 1 (data not shown). 
The median follow-up period for these patients was 3.1 
(1.7–5.0) years in men and 3.1 (1.7–5.1) in women. During 
follow-up, 170 (0.7%) men and 575 (2.3%) women were 
diagnosed with a sex-specific obesity-related cancer.
In men, no significant associations between BMI 
as a continuous or categorical variable and prostate 
cancer was found (tables 2 and 5). In women, BMI 
was associated with a higher risk of ovarian, endome-
trial and breast cancer in the age and fully adjusted 
analyses (HR 1.22 (95% CI 1.13 to 1.31) and HR 1.22 
(95% CI 1.14 to 1.32)). In the categorical analyses, a 
BMI of 25.0–30.0 kg/m2, a BMI of 30.0–35.0 kg/m2 and 
a BMI ≥35.0 kg/m2 were associated with a higher risk 
of ovarian, endometrial and breast cancer in women 
(table 2).
DIsCussIOn
The results of the present study showed that BMI was asso-
ciated with the total group of obesity-related cancers in 
both men and women with T2D. Important differences 
between men and women were found; BMI was associated 
with non-sex-specific obesity-related cancers in men, but 
not in women. Results concerning the sex-specific cancers 
showed that BMI was associated with ovarian, endome-
trial and postmenopausal breast cancer in women. No 
association between BMI and advanced prostate cancer 
was found in men.
This is the first study which describes the association 
between BMI and the total group of obesity-related 
cancers in a large cohort of men and women with T2D. A 
study from Japan could not find an association between 
BMI and all obesity-related cancers.6 However, this was 
a study that included 2334 patients of whom only 35 
patients developed cancer during follow-up.6
The absence of a significant association between BMI 
and non-sex-specific obesity-related cancers in women 
may indicate that BMI (in contrast to men) is not a 
risk factor for this group of cancers. Only one study 
has previously described sex differences in the associa-
tion between BMI and non-sex-specific obesity-related 
cancers in patients with T2D.8 A study from Sweden 
found that being overweight or obese was associated 
with a higher risk of gastrointestinal cancers in men, 
whereas in women only obesity but not overweight was 
found to be associated with gastrointestinal cancers.8 
The sex difference in the association between BMI and 
non-sex-specific obesity-related cancers could partly 
be the result of a sex difference in distribution of fat. 
In general, obese men have more intra-abdominal fat 
compared with obese premenopausal women. Although 
the sex difference in intra-abdominal fat is less apparent 
in patients with T2D, the amount of intra-abdominal fat 
is probably still higher in men.11 Especially, this abdom-
inal adiposity is associated with many metabolic abnor-
malities which may increases cancer risk. It might be that 
BMI was not accurate enough to represent the amount of 
abdominal fat especially in women with T2D. Using waist 
circumference as a marker of abdominal fat might have 
been more accurate.
In the present study, obese women had a 51% higher 
risk for ovarian, endometrial and postmenopausal breast 
cancer compared with lean women with T2D during 
follow-up. Only one previous study has described an asso-
ciation between BMI and sex-specific cancers in women 
with T2D. Miao Jonasson et al described a 39% higher 
risk for postmenopausal breast cancer compared with 
lean women.8 The association of BMI with these types of 
cancer might be attributed to an increase in oestrogen 
production in adipose tissue in overweight and obese 
women with T2D.12 BMI and T2D itself have been found 
to be related to a higher risk of endometrial and breast 
cancer.3 Taken this together, this indicates that especially 
obese women with T2D are at risk for the development of 
endometrial cancer and postmenopausal breast cancer. 
On the other hand, some researchers have questioned 
the relation between T2D itself and breast cancer. They 
have suggested that the higher risk of postmenopausal 
breast cancer in women with T2D could be completely 
explained by residual confounding by overweight and not 
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by having a problem with metabolic disturbance related 
to glucose control.13
In line with the results of the present study, Miao 
Jonasson et al could not find an association between BMI 
and prostate cancer in men with T2D.8 However, they 
included all prostate cancers, whereas only advanced 
prostate cancer is described by the World Cancer 
Research Fund to be related with BMI in the general 
population.5 Nevertheless, the International Agency 
for Research on Cancer Working Group has recently 
described that evidence for a preventive effect of the 
absence of excess body fat for fatal prostate cancer is 
limited.14 The present study adds to the literature that 
a relation between BMI and advanced prostate cancer 
is not present, at least not in men with T2D. Advanced 
prostate cancer should therefore be reconsidered as 
being obesity-related.
The strengths of the present study were the prospec-
tive design and the use of a large cohort of patients with 
T2D of which data on BMI were available. Some limita-
tions of the present study should also be mentioned. 
First, the study population consisted only of patients 
with T2D who are treated in primary care. Patients in 
secondary care often have worse manifestations of T2D 
and might therefore have a higher cancer risk. Although 
this limitation implies that the generalisability of our 
results is limited to primary care, it is still representative 
for a large part of the T2D population due to the fact 
that the majority (>85%) of the patients with T2D are 
treated in primary care in the Netherlands.15
Second, the clinical data and the data on medication 
use of the ZODIAC cohort were collected annually by 
practice nurses and GPs. The reliability of the data is 
therefore dependent on their accuracy. Third, data on 
BMI were missing for 9% of the patients. BMI values for 
these patients were estimated using multiple imputations. 
Fourth, the grouping of obesity-related cancers could 
be discussed. All different cancers were taken together 
as the number of total events would be too small when 
investigating each of the obesity-related cancers, sepa-
rately. Nevertheless, separate analyses would have been 
better. Finally, the follow-up period was relatively short for 
cancer epidemiology and therefore the number of events 
is relatively small.
COnClusIOns
In men with T2D BMI is associated with the total group 
of obesity-related cancers and with non-sex-specific 
obesity-related cancers. However, BMI is not related to 
advanced prostate cancer. The present study provides 
an extra argument for questioning advanced prostate 
cancer being obesity-related, at least in men with T2D. 
In women, BMI is associated with the total group of 
obesity-related cancers and with ovarian, endometrial 
and postmenopausal breast cancer. BMI is not related 
to non-sex-specific obesity-related cancers in women 
with T2D.
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